Over at In the Pipeline, Derek Lowe wonders what compounds might make good metabolic disease targets, harkening back to one put out there in 2002 by a company called Sumitomo Pharmaceuticals. He sees promise in CAMKK2, in that it's more upstream and involved in numerous pathways for regulation of appetite and glucose levels, including ghrelin, AMPK, and NPY.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.